ReviewCurrent diabetes reports2019
Advanced Technology in the Management of Diabetes: Which Comes First-Continuous Glucose Monitor or Insulin Pump?
Review in Current diabetes reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.Diabetes technology & therapeutics · 2023Trial
- A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.Lancet (London, England) · 2021Trial
- Home Visits for Children and Adolescents with Uncontrolled Type 1 Diabetes.Diabetes technology & therapeutics · 2020Trial
- Microneedle-Based Continuous Levodopa Monitoring in Patients with Parkinson's Disease.ACS sensors · 2026Article
- User evaluation of the Hypo-METRICS app: A tool for real-time symptom reporting of hypoglycaemia.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- A Glucose-Responsive Cannula for Automated and Electronics-Free Insulin Delivery.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Diabetes technology and sexual health: which role?Journal of endocrinological investigation · 2024Review
- Real-Time Continuous Glucose Monitoring Reduced Costly Diabetes-Related Events in Adolescents and Young Adults despite Lack of Short-Term Reduction in Hemoglobin A1c.Pediatric diabetes · 2023Article
- Delivering evidence-based interventions for type 1 diabetes in the virtual world - A review of UK practice during the SARS-CoV-2 pandemic.Diabetes research and clinical practice · 2022Review
- Patient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin delivery.Frontiers in endocrinology · 2022Article
- Type 1 Diabetes Management With Technology: Patterns of Utilization and Effects on Glucose Control Using Real-World Evidence.Clinical diabetes : a publication of the American Diabetes Association · 2021Article
- Glycemic Status Assessment by the Latest Glucose Monitoring Technologies.International journal of molecular sciences · 2020Review
- Glycemic variability: adverse clinical outcomes and how to improve it?Cardiovascular diabetology · 2020Review
- Changing costs of type 1 diabetes care among US children and adolescents.Pediatric diabetes · 2020Article
- Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain.BMJ open diabetes research & care · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewIn this article, we consider advanced technologies for the management of diabetes. RECENT
findingsSpecifically, we pose the question of which should come first: an insulin pump (CSII) or a continuous glucose monitor (CGM)? Historical perspective on both insulin delivery and glucose measurement is provided. Recently published clinical trials are reviewed. Practical issues including quality of life, patient education, and out-of-pocket cost are discussed. Based on available evidence and clinical experience, we favor CGM as a first-line technology recommendation for the treatment of type 1 diabetes (T1D).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.